Search clinical trials for: Placebo to sitagliptin

Total 60579 results

AstraZeneca

Completed

Mechanistic Evaluation of Glucose-lowering Strategies in Patients With Heart Failure (MEASURE-HF)

Heart Failure | Type 2 Diabetes Mellitus

United States, Thailand, Korea, Republic of, Russian Federation, Ukraine, Hungary, Bulgaria, Chile, Canada, Romania
Merck Sharp & Dohme LLC

Completed

A Pooled Analysis of the Safety and Efficacy of MK-0431A and MK-0431A XR in Pediatric Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Therapy (Alone or in Combination With Insulin) (MK-0431A-170/MK-0431A-289)

Type 2 Diabetes Mellitus
Boehringer Ingelheim

Completed

The Effect of Linagliptin (BI 1356) on 24h-glucose Control and Various Biomarkers in Type 2 Diabetic Patients

Diabetes Mellitus, Type 2

Germany
Emory University
Merck Sharp & Dohme LLC

Terminated

DPP-4 Inhibition and TZD for DM Prevention (DInT DM)

Prediabetic State

United States
AstraZeneca

Completed

Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone

Type 2 Diabetes

United States, Hungary, Mexico, South Africa, Romania, Poland
Merck Sharp & Dohme LLC

Completed

Omarigliptin (MK-3102) Clinical Trial - Placebo- and Sitagliptin-Controlled Monotherapy Study in Japanese Patients With Type 2 Diabetes Mellitus (MK-3102-020)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Efficacy and Safety of Sitagliptin and MK0431A in Comparison to a Commonly Used Medication in Patients With Type 2 Diabetes (0431-068)(COMPLETED)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

An Investigational Drug in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (0431-028)(COMPLETED)

Diabetes Mellitus, Type 2 | Chronic Renal Insufficiency
Kallyope Inc.

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 in Healthy Overweight/Obese Volunteers

Obesity

United States
Merck Sharp & Dohme LLC

Completed

Sitagliptin and Pioglitazone Mechanism of Action Study in Type 2 Diabetes Mellitus (0431-061)

Type 2 Diabetes Mellitus (T2DM)
Boehringer Ingelheim
Eli Lilly and Company

Completed

Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Belgium, Canada, China, Germany, India, Ireland, Japan, Switzerland
Merck Sharp & Dohme LLC

Completed

A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

MK0431 and Pioglitazone Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-102 AM2)

Type 2 Diabetes Mellitus
University of Sao Paulo General Hospital
InCor Heart Institute

Completed

DPP-4 Inhibitors and Acute Myocardial Infarction:Effects on Platelet Function

Platelet Aggregation During Acute Myocardial Infarction

Brazil
AstraZeneca
Bristol-Myers Squibb

Completed

18-week add-on to Metformin Comparison of Saxagliptin and Sitagliptin in Adult Patients With Type 2 Diabetes (T2D)

Type 2 Diabetes

Mexico, South Africa, Norway, Argentina, Belgium, Denmark, Sweden, France, Italy
Merck Sharp & Dohme LLC
Pfizer

Completed

Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

A Study of Different Doses of Sitagliptin (MK-0431) in Participants With Type 2 Diabetes Mellitus (MK-0431-014)

Type II Diabetes Mellitus
Alexandria University

Recruiting

Cognitive Protective Effect of Newer Antidiabetic Drugs

Type 2 Diabetes

Egypt
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety of Sitagliptin/Metformin Fixed-Dose Combination (FDC) Compared to Glimepiride in Participants With Type 2 Diabetes Mellitus (MK-0431A-202)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Participants With Type 2 Diabetes Mellitus (MK-0431-251)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Terminated

A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Study to Assess Safety & Efficacy of Sitagliptin as Initial Oral Therapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants. (MK-0431-083)

Diabetes Mellitus | Type 2 Diabetes
Merck Sharp & Dohme LLC

Terminated

A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

A Study Comparing the Pharmacokinetic and Pharmacodynamic Profiles for Sitagliptin, Saxagliptin and Vildagliptin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-142)

Type 2 Diabetes Mellitus
Brigham and Women's Hospital
Patient-Centered Outcomes Research Institute; McGill University; VA Boston Healthcare...

Active, not recruiting

Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study (CER-4-T2D)

Type2 Diabetes | Renal Disease | Cardiovascular Events

United States
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of DBPR108 100 mg in Type 2 Diabetes Mellitus Patients

Type 2 Diabetes Mellitus

China
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety and Efficacy of Sitagliptin 100 mg in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (MK-0431-229)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Dose Response Finding Study of MK-0431/ONO-5435 in Japanese Subjects With Impaired Glucose Tolerance (MK-0431-105)

Glucose Intolerance
University Hospital Inselspital, Berne
Fresenius Kabi

Completed

The Impact of Preoperative Oral Glutamine Intake on the Immunocompetence and Outcomes of Malnourished Patients Undergoing Major Abdominal Surgery Due to Malignancies (Glutaminprojec)

Malnourishment | Gastrointestinal Tumors

Switzerland
Merck Sharp & Dohme LLC

Completed

Study to Evaluate the Safety and Efficacy of the Addition of Omarigliptin (MK-3102) Compared With the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)

Type 2 Diabetes
Lund University
Merck Sharp & Dohme LLC

Completed

Sitagliptin and Glucagon Counterregulation (SITACLAMP)

Type 2 Diabetes

Sweden
Merck Sharp & Dohme LLC

Completed

Initial Combination With Pioglitazone Study (0431-064)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Randomized Sitagliptin Withdrawal Study (MK-0431-845)

Type 2 Diabetes Mellitus
Li Bo

Completed

Effect of Sitagliptin on Progression of Coronary Intermediate Lesion

Type 2 Diabetes Mellitus | Atherosclerosis

China
University of Colorado, Denver
Merck Sharp & Dohme LLC

Completed

Impact of Sitagliptin on Cardiovascular Exercise Performance in Type 2 Diabetes

Cardiovascular Disease | Type 2 Diabetes

United States
Lundquist Institute for Biomedical Innovation at...
Emmaus Medical, Inc.

Terminated

L-Glutamine Therapy for Sickle Cell Anemia

Sickle Cell Anemia | Thalassemia

United States
Eli Lilly and Company

Completed

A Study of LY3325656 in Healthy Participants and Participants With Type 2 Diabetes

Diabetes Mellitus, Type 2

Singapore
Merck Sharp & Dohme LLC

Completed

Sitagliptin Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus (T2DM)
University of Southern California

Completed

Sitagliptin Effects on Arterial Vasculature and Inflammation in Obesity (SAVORO)

Inflammation | Atherosclerosis

United States
Merck Sharp & Dohme LLC
Pfizer

Completed

Study Of Safety And Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-016)

Diabetes Mellitus, Type 2
Shanghai Jiao Tong University School of Medicine

Unknown

Study on Exploring the Effect of DPP-4 Inhibitors on β-cell Function by Using the Two-step Hyperglycemic Clamp

Type 2 Diabetes

China
Merck Sharp & Dohme LLC
Pfizer

Completed

Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)

Type 2 Diabetes Mellitus
Astellas Pharma Inc

Completed

A Study to Assess the Safety and Efficacy of ASP1941 in Combination With Dipeptidyl Peptidase-4 (DPP-4) Inhibitor in Type 2 Diabetic Patients

Type 2 Diabetes Mellitus

Japan
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Sitagliptin for Reducing Inflammation and Immune Activation

HIV-1 Infection

United States
Eurofarma Laboratorios S.A.

Completed

Evogliptin in Type 2 Diabetes Mellitus (EVOLUTION: EVOgLiptina no Diabetes Mellitus TIpO 2) (EVOLUTION)

Diabetes Mellitus, Type 2

Brazil
University Health Network, Toronto
Merck Sharp & Dohme LLC

Completed

The INDORSE Study: Inhibition of Dipeptidyl Peptidase IV: Outcomes on Renal Sodium Excretion (INDORSE)

Type 2 Diabetes

Canada
NeuroBo Pharmaceuticals Inc.

Recruiting

Study to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed NASH

NON-ALCOHOLIC STEATOHEPATITIS

United States
Novo Nordisk A/S

Completed

A Research Study Comparing a New Medicine Oral Semaglutide to Sitagliptin in People With Type 2 Diabetes (PIONEER 12)

Diabetes Mellitus, Type 2

Serbia, South Africa, Taiwan, Romania, Algeria, Hong Kong, Brazil, China, Czechia
Lin Liao

Unknown

Efficacy and Safety Comparative Study of Sitagliptin,Vildagliptin and Saxagliptin

Type 2 Diabetes Mellitus

China
LG Life Sciences

Completed

A Phase IIIb Study to Evaluate the Safety and Efficacy of Gemigliptin in Type 2 Diabetes Mellitus Patients With Moderate or Severe Renal Impairment(GUARD Study) (GUARD)

Type 2 DM Patients With Moderate or Severe Renal Impairment

Korea, Republic of

3

Subscribe